熱門資訊> 正文

Niagen Bioscience表示Niagen IV已在全国近600家诊所使用

2025-05-05 20:52

Niagen Bioscience (NASDAQ:NAGE) announced on Monday the continued expansion of its clinical footprint, with additional new clinics now offering pharmaceutical-grade Niagen IV and injections featuring patented nicotinamide riboside.
These new providers join a growing network of almost 600 clinics nationwide offering the pharmaceutical-grade NAD-boosting Niagen IV therapy.
Niagen Bioscience (NASDAQ:NAGE) shares were up 0.37% in premarket trading.

More on ChromaDex

ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High
ChromaDex Corporation 2024 Q4 - Results - Earnings Call Presentation
ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript
ChromaDex GAAP EPS of $0.09 beats by $0.07, revenue of $29.1M beats by $2.59M
Seeking Alpha’s Quant Rating on ChromaDex

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。